Personnel

Ligand appoints John L. Higgins CEO

Published in Healthcare Finance, Tax and Law Weekly, February 14th, 2007

Ligand Pharmaceuticals, Inc., (LGND) announced that John L. Higgins is joining the company as CEO, president, and a member of the company's board of directors.

Higgins succeeds Henry F. Blissenbach who has served as chairman and interim CEO since August 2006.

Blissenbach will continue as chairman of the board of directors.

Higgins brings to Ligand over 14 years of corporate development, financing, strategic planning, commercialization, and investment banking experience in the biopharmaceutical industry. Prior to joining Ligand, Higgins was CFO, executive vice president, finance, administration, and corporate development of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2007-02-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry